Galectin Therapeutics to Present at 29th Annual ROTH Conference

NORCROSS, Ga., March 09, 2017 -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Harold Shlevin, Ph.D., the Company's chief operating officer, will present at the 29th Annual ROTH Conference on Wednesday, March 15, 2017 at 11:30 a.m. Pacific Time. The conference is being held at the Ritz-Carlton in Dana Point, CA on March 12-15, 2017.

A live webcast of the presentation may be accessed on the conference’s website at http://wsw.com/webcast/roth31/galt. The webcast will be archived for 365 days following the live presentation on the Company’s website at www.galectintherapeutics.com.

About Galectin Therapeutics
Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver and skin diseases and cancer. Galectin’s lead drug (GR-MD-02) is a carbohydrate-based drug that inhibits the galectin-3 protein which is directly involved in multiple inflammatory, fibrotic, and malignant diseases. The lead development program is in non-alcoholic steatohepatitis (NASH) with cirrhosis, the most advanced form of NASH related fibrosis. This is the most common liver disease and one of the largest drug development opportunities available today. Additional development programs are in treatment of severe atopic dermatitis, moderate-to-severe plaque psoriasis, and in combination immunotherapy for advanced melanoma and other malignancies. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development.  Additional information is available at www.galectintherapeutics.com.

Contacts: 
Jack Callicutt, Chief Financial Officer 
(678) 620-3186
[email protected]